Page 761 - Clinical Hematology_ Theory _ Procedures ( PDFDrive )

Index 745

laboratory assessment o Blood vasculature, structure and unction plasma cells, 595
activated partial thromboplastin time arteries and veins, 490, 490 polymorphonuclear segmented neutrophils,

(aP ), 535–536 arterioles and venules, 490 594, 595t
prothrombin time (P ), 534–535 capillaries, 490–491 Cell-Dyn Series, 624–625
pathways Body uid analysis Cell unctioning analysis, 638
extrinsic coagulation pathway, 530, 530 amniotic uid, 608–609 Cell sorting, 638

brin ormation, 531 anatomical sites, 584, 584t Cellular identi cation, 622–623, 623
nal common pathway, 531 blood-brain barrier, 585 Cellular proteases, 544
intrinsic coagulation pathway, 530–531, 531 cerebrospinal uid (see Cerebrospinal uid) Cellulose acetate electrophoresis, 131
plasma clot-based mechanism, 530 pericardial uid (see Pericardial uid) Cellulose acetate method, hemoglobin

prekallikrein (PK), 530 peritoneal uid (see Peritoneal uid) electrophoresis
protease inhibitors, 534 pleural uid (see Pleural uid) alkaline electrophoresis, 681, 682
proteins, 527, 527t preparation, 608 analysis, 682–683
prothrombin group, 528 seminal uid (see Seminal uid) chromatography, 682

specialized coagulation testing staining o , 608 citrate agar electrophoresis, 682
activated clotting time (AC ), 536 standard precautions, 584 denaturation procedures, 682, 682
anticoagulants, 537 synovial uid (see Synovial uid) principle, 681
chromogenic anti-Xa method, 537 tanycytes, 585 Centers or Disease Control and Prevention

clot wave orm analysis (CWA), 536 Bone marrow, 83–86, 89 (CDC), 2
ecarin clotting time (EC ), 536 examination, 680, 680–681 Centrioles, 62, 67, 68
actor de ciency, 536 anemia, 234–235 Cephalic vein, 39
nonspeci c inhibitors, 537 aspiration sites, 49 Cerebral small vessel disease, 506

speci c actor inhibitors, 537 principle, 49 Cerebrospinal uid (CSF)
thrombin-mediated reactions, 533 procedure, 50 cells dif erentiation procedure, 591
thromboplastins, 538 staining, 49 cellular dif erentiation, microscopic
Blood collection supplies and equipment, 49–50 examination

equipment ailure syndromes choroidal cells, 590
anticoagulant adverse ef ects, 30 genetic tests, 248t ependymal cells, 590
anticoagulants, 27–28 hematology, 244 erythrocytes, 590
capillary blood, 35–36 proli erative compartment, 165, 165 granulocytic cells, 590

evacuated tubes, 32–35 reserve, 165 immature cells, 590
order o draw, 34t Bone marrow ailures, single-cell lineage lymphocytes, 589
sa ety, 30–31 congenital dyserythropoietic anemia (CDA), malignant cells, 590
single-use needle holder, 31–32 250–251 mesothelial cells, 590

specimen separation, 28 cyclic neutropenia, 251–252 mononuclear phagocytes, 589–590
specimen storage and handling, 36–37 pure red cell aplasia (PRCA), 249–250 plasma cells, 590
standard needle, 30–31 severe congenital neutropenia (SCN), 251–252, cellular enumeration, microscopic
patients, 26–27 252t examination, 587

plasma, 27 Bordetella pertussis (Haemophilus pertussis) in ec- laboratory analysis
quality tion, 362 general principle, 586
assessment, 26 Brecker-Cronkite manual method, 692–693 gross physical examination, 586–587, 586t
patient care partnership, 26 Buf y coat smears preparation, 673–674 specimen, 586

phlebotomist, 26 Burkitt’s lymphoma lumbar puncture, specimen collection,
phlebotomy, 26 classi cation, 431 586, 586t
serum, 27 clinical signs and symptoms, 432, 432 production o , 585
techniques epidemiology, 431 Charcot–Leyden crystals, 166

blood lm preparation, 48–49 laboratory characteristics, 432 Chédiak-Higashi syndrome, 340t, 342–343, 343
blood smear preparation, 46 pathogenesis, 431–432 Chemical hygiene plan (CHP), 3
bone marrow examination, 49–50 Burr cells, 146, 147 Chemoimmunotherapy, 439
capillary blood collection, 45–46 Bursa, 189 Chemokinesis, 343

peripheral blood lms staining, 50 Chemotactic actors, 201
principles, staining, 50–51 C Chemotaxis, 177
protocol, 38 Cabot rings, 150, 151 Chemotherapy, 418
Push-Wedge method, 46–48 Calcium pyrophosphate dihydrate (CPPD), 605, Chemotherapy treatment, PV, 463

staining procedure, 51 606, 608 Chloride shi , 123
venous blood collection/phlebotomy, 38–46 Calibrated automated thrombogram, 540 Chloroma, 389, 453
Blood collection tubes Calibration, 15 Cholesterol crystals, 608
environmental actors Capillary blood collection Christmas disease, 552

altitude, 33–34 procedure termination, 46 Chroma n cells, 363
humidity, 34 sample collecting, 45–46 Chromatin, 63–64, 64
light, 34 site selection and preparation, 45 Chromogenic anti-Xa method, 537
temperature, 32–33 skin puncture, 45, 46 Chromosomal abnormalities, MDS

evacuated tube system (E S), 33 supplies and equipment, 45 consequences, 477
expiration dates, 34–35 Capillary electrophoresis (CE), 658, 659 cytogenetics to prognosis, 477–478, 481
order o draw, 34t Capture (tethering) process, 177 Chromosomes
stopper color, anticoagulants, 34t Carboxyhemoglobin, 129 alterations, 65–66

Blood disorders, 2 Cardiac tamponade, 600 banding techniques, 65, 67
Blood loss, 233 CBC (see Complete blood count (CBC)) clinical use, cytogenetics, 65
Blood loss related anemia CDC (see Centers or Disease Control and de nition, 65
acute Prevention) karyotype, 65, 66

clinical eatures, 240t Cell-based coagulation, 531 mitogen, 65
etiology, 239 Cell dif erential examination, CSF, 594 Chronic acquired red cell aplasia, 250
laboratory ndings, 239, 240t eosinophils, 594–595 Chronic blood loss anemia, 240–241, 240b
physiology, 239, 240b lymphocytes, 594 Chronic eosinophilic leukemia, not otherwise

chronic, 240–241, 240b mesothelial cells, 595–596 speci ed (CEL-NOS), 459
Blood smear, evaluation, 601 mononuclear cells, 594 Chronic granulomatous disease (CGD), 340t, 344